10-K Decoder · All companies

Travere Therapeutics, Inc.

TVTX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$491M$233M+110%
Operating income−$62.8M−$324M+80.6%
Net income−$25.6M−$322M+92.1%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 2, 2026

$Q3 2026Year earlierChange
Revenue$225M$165M+36.2%
Operating income−$68.1M$24.9M
Net income−$52.3M$25.7M

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Travere's revenue in FY2025?
$491M in FY2025 (Fiscal year ended Dec 31, 2025), +110% vs $233M a year earlier, per its 10-K filed Feb 2026.
Was Travere profitable in FY2025?
No: net income was −$25.6M and operating income −$62.8M in FY2025.
What was Travere's revenue in Q3 2026?
$225M (+36.2% vs a year earlier), per its Form 10-Q filed Nov 2, 2026.